ADT1667-Tovetumab Biosimilar-(PDGFRA / PDGFR2/ CD140a)-Research Biosimilar Antibody
- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1667 |
Product Name |
ADT1667-Tovetumab Biosimilar-(PDGFRA / PDGFR2/ CD140a)-Research Biosimilar Antibody |
Alias |
MEDI-575 |
Clonity |
Monoclonal |
|
Alternate Names anti-mouse PDGFRA antibody, anti-PDGFRA antibody, anti PDGFRA antibody, recombinant PDGFRA , PDGFRA antibody, anti-PDGFRA monoclonal antibody, PDGFRA antibodies, PDGFRA recombinant antibody, PDGFRA blocking antibody, PDGFR2 recombinant antibody, PDGFR2 blocking antibody, CD140a recombinant antibody, CD140a blocking antibody |
|
Host |
CHO Cells |
Species |
Human |
Target |
PDGFRA/PDGFR2/CD140a |
Isotype |
IgG2 Kappa |
Size |
1mg, 5mg |
Research Area |
Cancer |
CAS Number |
1243266-04-7 |
Product Description |
Tovetumab is an anti-PDGFRa monoclonal antibody designed for the treatment of cancer. It was developed by MedImmune, and trialed for use in glioblastoma and non-small cell lung cancer. Development was discontinued in 2013. This drug was developed by MedImmune, LLC. |
Application |
IP, IF, Functional assay, FC, Neut, ELISA, ICC |
Purity |
>95% as determined by SDS-PAGE |
Concentration |
batch dependent |
Buffer |
Supplied in PBS, PH7.5 |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
Shipping Condition |
Shipped on ice packs. |
Note |
This product is for research use only. |
Reference |
1. Heinrich et al. (2003) identified PDGFRA mutations in GIST (Science).
2. WHO Classification of Tumours (2020) outlines molecular subtypes of GIST.
3. FDA approval of avapritinib (2020) for PDGFRA exon 18-mutant GIST.
|